A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy
about
Harnessing the Microbiome to Enhance Cancer ImmunotherapyRelapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinityMHC-Ig induces memory T cell formation in vivo and inhibits tumour growth.miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.miR-155 releases the brakes on antitumor T cells.STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing miceThe Immunotherapy Roadmap.Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.The use of agonistic anti-CD40 therapy in treatments for cancer.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Peptide vaccines in cancer-old concept revisited.A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway.An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects.Effective antitumor peptide vaccines can induce severe autoimmune pathology.Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes.Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
P2860
Q28088598-92EF4CF1-2450-444D-9FF5-F2BE833BD5ABQ30413827-EF32055D-4C31-4849-BC06-9E1309B204D2Q34641196-FAB4E0C0-D30D-4762-80EA-1689D1E20716Q34985536-4D18D19D-C641-4F62-8AEB-134567D105A9Q35130794-4A145887-3BE6-4847-B244-19CF8A7E54B5Q35212733-4F4303C6-7C2C-43C3-8F95-B49C12C3A354Q36060338-89F13733-A00B-41A9-9396-724F57C2A848Q36288074-6DAFBC19-0589-44AF-8FA3-2C49462A9742Q36471488-5613DC21-9F61-4EF2-B338-D93280B9EEF2Q37641401-68CAAEEA-80F7-47A5-B1BF-1E7E7EF14ADFQ38026924-A7541C28-5D07-496E-A9FE-470AEDC01024Q38149916-03CB2F38-6ECF-41E9-AF10-D2CDA2A0017AQ39035351-37AD0D48-6EE7-4E51-B624-C5C49F18B69BQ40877648-3A8BD93D-9A80-4524-BC63-536ACA75B85DQ41242778-146FF4A7-578F-4C44-A255-AD18969A022AQ42378431-0C19D1F6-F066-4631-8E1E-D117A8B1F54DQ46604950-0DDDEBC1-61C1-491D-8B97-F969E6CA4E6BQ47162004-AFF0E2F7-6114-480F-8F86-15AF9E894720Q52775663-59BDAA30-81D3-461F-80DF-EA7CDF12E8E3
P2860
A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A potent vaccination strategy ...... itumor adoptive T-cell therapy
@en
type
label
A potent vaccination strategy ...... itumor adoptive T-cell therapy
@en
prefLabel
A potent vaccination strategy ...... itumor adoptive T-cell therapy
@en
P2093
P2860
P1433
P1476
A potent vaccination strategy ...... itumor adoptive T-cell therapy
@en
P2093
Eduardo Reyes-Vargas
Esteban Celis
Hyun-Il Cho
Julio C Delgado
P2860
P304
P356
10.1158/0008-5472.CAN-11-3246
P407
P577
2012-02-24T00:00:00Z